OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
6785$126.0055

Alar Pharmaceuticals Inc

PharmaceuticalsVerified

Alar Pharmaceuticals Inc maintains a strong liquidity position with a current ratio of 35.07, indicating a significant buffer of current assets relative to current liabilities. The company's cash and equivalents amount to 559,063,000 TWD, which supports its operational flexibility and financial stability. The price-to-book ratio of 3.25 suggests that the market values the company at a premium to its book value, reflecting investor confidence in its intangible assets and future earnings potential. In terms of profitability, Alar Pharmaceuticals Inc reported a net income of 12,049,000 TWD, but experienced an operating loss of 22,106,000 TWD. The return on equity of 0.47% and return on assets of 0.45% indicate that the company is generating modest returns relative to its equity and asset base. These metrics are below the typical thresholds for pharmaceutical companies, which often require higher returns to justify the high R&D expenditures and long development cycles. The company's revenue is not disclosed in the latest financial snapshot, making it difficult to assess geographic and segment exposure. However, the absence of detailed segment data suggests that Alar Pharmaceuticals Inc may have a concentrated business model, potentially increasing its vulnerability to market-specific risks. Looking at the growth trajectory, the company's operating cash flow of 9,987,000 TWD and free cash flow of 11,957,000 TWD indicate a positive cash flow generation capability. However, the lack of revenue data and the operating loss suggest that the company is in a growth phase with significant investment in R&D and product development. The risk assessment for Alar Pharmaceuticals Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's capital structure is characterized by minimal debt, with long-term debt amounting to only 1,082,000 TWD. This conservative approach to debt management reduces financial leverage and interest rate exposure. Recent events and filings do not show any significant changes in the company's financial or operational status. The company's financial snapshot does not include recent events or transcripts, suggesting that there are no material developments to report at this time.

30-day price · 6785-42.50 (-25.2%)
Low$121.50High$178.00Close$126.00As of21 May, 00:00 UTC
Profile
CompanyAlar Pharmaceuticals Inc
Ticker6785.TWO
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Alar Pharmaceuticals Inc is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the oncology and rare disease therapeutic areas.

Classification. Alar Pharmaceuticals Inc is classified in the Pharmaceuticals industry under the Healthcare economic sector with a confidence level of 0.92.

Alar Pharmaceuticals Inc maintains a strong liquidity position with a current ratio of 35.07, indicating a significant buffer of current assets relative to current liabilities. The company's cash and equivalents amount to 559,063,000 TWD, which supports its operational flexibility and financial stability. The price-to-book ratio of 3.25 suggests that the market values the company at a premium to its book value, reflecting investor confidence in its intangible assets and future earnings potential. In terms of profitability, Alar Pharmaceuticals Inc reported a net income of 12,049,000 TWD, but experienced an operating loss of 22,106,000 TWD. The return on equity of 0.47% and return on assets of 0.45% indicate that the company is generating modest returns relative to its equity and asset base. These metrics are below the typical thresholds for pharmaceutical companies, which often require higher returns to justify the high R&D expenditures and long development cycles. The company's revenue is not disclosed in the latest financial snapshot, making it difficult to assess geographic and segment exposure. However, the absence of detailed segment data suggests that Alar Pharmaceuticals Inc may have a concentrated business model, potentially increasing its vulnerability to market-specific risks. Looking at the growth trajectory, the company's operating cash flow of 9,987,000 TWD and free cash flow of 11,957,000 TWD indicate a positive cash flow generation capability. However, the lack of revenue data and the operating loss suggest that the company is in a growth phase with significant investment in R&D and product development. The risk assessment for Alar Pharmaceuticals Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's capital structure is characterized by minimal debt, with long-term debt amounting to only 1,082,000 TWD. This conservative approach to debt management reduces financial leverage and interest rate exposure. Recent events and filings do not show any significant changes in the company's financial or operational status. The company's financial snapshot does not include recent events or transcripts, suggesting that there are no material developments to report at this time.
Key takeaways
  • Alar Pharmaceuticals Inc has a strong liquidity position with a current ratio of 35.07 and significant cash reserves.
  • The company is generating modest returns on equity and assets, which are below typical thresholds for pharmaceutical companies.
  • The absence of detailed revenue and segment data suggests a potentially concentrated business model.
  • The company's positive cash flow generation capability is a positive sign, but the operating loss indicates ongoing investment in growth.
  • The company's conservative capital structure with minimal debt reduces financial leverage and interest rate exposure.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "The company's operating margin is negative, indicating that it is not currently profitable from operations, which is a concern for future margin expansion.",
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$0.00
Gross profit
Operating income-$22.1M
Net income$12.0M
R&D
SG&A
D&A
SBC
Operating cash flow$10.0M
CapEx-$1.0M
Free cash flow$12.0M
Total assets$2.67B
Total liabilities$79.3M
Total equity$2.59B
Cash & equivalents$559.1M
Long-term debt$1.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$0.00-$93.3M-$64.2M-$62.4M
FY-3$800.0k-$46.5M-$19.9M-$17.8M
FY-2$469.3M$385.5M$382.6M$379.6M
FY-1$5.8M-$67.9M$18.2M-$79.4M
FY0$2.8M-$167.8M-$79.7M-$94.4M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$539.9M$534.4M$121.8M
FY-3$522.6M$514.5M$214.0M
FY-2$973.2M$897.1M$532.1M
FY-1$2.56B$2.49B$1.35B
FY0$2.49B$2.40B$1.76B
PeriodOCFCapExFCFSBC
FY-4-$63.5M-$1.6M-$62.4M
FY-3-$32.9M-$1.1M-$17.8M
FY-2$403.6M-$6.3M$379.6M
FY-1-$37.7M-$1.2M-$79.4M
FY0-$171.0M-$2.9M-$94.4M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$0.00-$22.1M$12.0M$12.0M
FQ-6$0.00-$16.9M-$3.5M-$3.3M
FQ-5$5.8M-$9.7M-$15.2M-$15.3M
FQ-4$0.00-$19.2M$24.9M$27.5M
FQ-3$0.00-$43.6M-$2.1M-$1.1M
FQ-2$1.3M-$11.8M-$25.1M-$24.1M
FQ-1$0.00-$56.1M-$27.1M-$26.6M
FQ0$1.5M-$56.2M-$25.4M-$25.8M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$2.67B$2.59B$559.1M
FQ-6$2.55B$2.48B$571.6M
FQ-5$2.52B$2.47B$847.7M
FQ-4$2.56B$2.49B$1.35B
FQ-3$2.56B$2.49B$385.8M
FQ-2$2.52B$2.45B$1.44B
FQ-1$2.52B$2.42B$1.74B
FQ0$2.49B$2.40B$1.76B
PeriodOCFCapExFCFSBC
FQ-7$10.0M-$1.0M$12.0M
FQ-6-$16.6M-$1.7M-$3.3M
FQ-5-$55.2M-$2.8M-$15.3M
FQ-4-$37.7M-$1.2M$27.5M
FQ-3-$44.7M-$1.1M
FQ-2-$36.8M-$81.0k-$24.1M
FQ-1-$87.7M-$932.0k-$26.6M
FQ0-$171.0M-$2.9M-$25.8M
Valuation
Market price$126.00
Market cap$8.42B
Enterprise value$7.86B
P/E698.5
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF786.9
P/B3.2
P/Tangible book3.2
Tangible book$2.59B
Net cash$558.0M
Current ratio35.1
Debt/Equity0.0
ROA0.4%
ROE0.5%
Cash conversion83.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
Metric6785Activity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity0.0%9.3% medp25 0.1% · p75 43.8%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 06:40 UTC#ce70a93b
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 02:13 UTCJob: b4ff9e1f